Interestingly, the mutation rate of FAT1 is significantly greater in HPV‐ HNSCC compared to HPV+ HNSCC, underscoring the importance of FAT1 mutations in the molecular landscape of HNSCC and suggests that FAT1 may serve as a critical biomarker or therapeutic target, particularly in HPV‐ cases. The gene discussed is FAT1; the disease is head and neck squamous cell carcinoma.